This 2016 review explores the role of methylated circulating tumor DNA (ctDNA) as a non-invasive biomarker in cancer prognosis and treatment monitoring. ctDNA, detectable in plasma or serum, reflects tumor-specific genetic and epigenetic alterations, including aberrant DNA methylation patterns. These methylation changes are often consistent across patients, making them reliable
